Apr 01, 2025 9:00 am EDT Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Mar 19, 2025 4:05 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Mar 17, 2025 9:25 am EDT Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Mar 11, 2025 9:00 am EDT Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Mar 07, 2025 9:25 am EST Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Mar 04, 2025 7:00 am EST Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Jan 02, 2025 9:15 am EST Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Nov 20, 2024 9:00 am EST Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency